AYTU BIOPHARMA, INC (AYTU): Nasdaq/NYSE listing notice — Aytu BioPharma receives 180-day Nasdaq extension to May 2023 to regain $1 bid price compliance

AYTU BIOPHARMA, INC

Nasdaq granted 180-day extension to May 22, 2023 to meet minimum bid price of $1.00 per share.
Stockholders approved reverse stock split up to 1-for-20; board may enact before Oct 4, 2023.
If not compliant by May 22, 2023, Nasdaq will delist common stock; company may appeal.
Failure to regain compliance could lead to delisting; no assurance appeal would succeed.
Extension has no immediate effect on listing or trading under symbol AYTU.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

AYTU BIOPHARMA, INC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

November 22, 2022 the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to May 22, 2023, to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Company intends to actively monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options to regain compliance with the Bid Price Rule under the Nasdaq Listing Rules, including enacting a reverse stock split. On October 5, 2022, the Company’s stockholders approved an amendment to its Cer

View on SEC.gov

Browse all listing & compliance notices →

AYTU BIOPHARMA, INC filing history →

Source: SEC EDGAR

accession 0001558370-22-018148

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.